Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report
This case highlights the efficacy of pemigatinib-based systemic therapy in achieving tumor regression and enabling curative resection in locally recurrent FGFR-2-positive ICC. The successful outcome underscores the potential of targeted therapies in managing recurrent ICC, warranting further investigation.
Authors
- Lihan Qian (ORCID: https://orcid.org/0009-0007-8703-7429)
- Jingfeng Li (ORCID: https://orcid.org/0000-0002-2010-5729)
- Yongjun Chen (ORCID: https://orcid.org/0000-0002-6486-2000)
- Junqing Wang (ORCID: https://orcid.org/0000-0003-1219-639X)
- Yuchen Yang (ORCID: https://orcid.org/0000-0002-4255-2888)
- Di Ma (ORCID: https://orcid.org/0000-0001-5067-874X)
- Jing Xie (ORCID: https://orcid.org/0009-0004-8556-2295)
- Weixia Li (ORCID: https://orcid.org/0000-0001-5945-6350)
- Fengjie Hao
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fonc.2025.1527372
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ruijin Hospital